Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosén E, Aarsland D, Visser PJ, Schröder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttilä T, Wallin A, Jönhagen ME, Minthon L, Winblad B, Blennow K. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. 2009 Jul 22;302(4):385-93. PubMed.

Recommends

Please login to recommend the paper.

Comments

  1. All these observations of amyloid deposition in prodromal AD clearly demonstrate that amyloidosis is an early marker of a pathological process that will lead to AD dementia. Accordingly, they also demonstrate that preamyloid, oligomer deposition has not this huge toxicity that makes hot headlines.

    View all comments by Andre Delacourte

Make a Comment

To make a comment you must login or register.

This paper appears in the following:

News

  1. Multi-Paper Alert: More Data That Brain Amyloid Is Bad for You
  2. St. Louis: Biomarkers Pre-dementia—Like eFAD, Like LOAD?
  3. CSF Testing for AD: Single-center Bliss, Multicenter Woe?
  4. Worldwide Quality Control Set to Tame Biomarker Variation
  5. Cochrane Asks for Field’s Input on Draft Reporting Standards
  6. CSF Biomarkers Track With Atrophy, Cognition in Normal Aging
  7. Tau Biomarkers—More Informative Fragments in Spinal Fluid?

Webinars

  1. Untapped Resource? New Study to Boost Acceptance of CSF Analysis